BioSpace News Archive

Portage Biotech Inc. is pleased to announce that the US Patent Office has granted Stimunity its main patent, US2016/074507, entitled “Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response.”

Seattle Genetics, Inc. (Nasdaq:SGEN) today highlighted data from the phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy in newly diagnosed stage III or IV classical Hodgkin lymphoma (HL) at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

Alexo Therapeutics presented data from the first-in-human Phase 1 study of its lead candidate, ALX148, at the American Society of Clinical Oncology (ASCO) Annual Meeting.

The University of Mount Union is proud to announce it is adding a second degree accelerated Bachelor of Science in Nursing (BSN) program to its successful Department of Nursing.

RGX-104 shown to be well-tolerated and capable of generating immunologic and anti-tumor activity in advanced cancer patients. Rgenix continues Phase Ia/b trial with a RGX-104 monotherapy expansion cohort and dose escalation/ expansion cohorts of RGX-104 in combination with nivolumab.

Positive Results Support Development Pathway of AL101 as a Targeted Therapy for Patients with Tumors That Have Activating Notch Mutations

Much needed more efficient manufacturing processes aren’t being completed by pharma for ADCs.

This new and effective methodology will provide a more efficient method to combat one of the most aggressive forms of breast cancer.

Mr. Coleman will be responsible for sourcing and leading financing assignments for biopharma and medtech companies on a global basis

The Biotechnology Institute announced the 15 student winners who will advance to the final stages of the 2018 BioGENEius Challenge this coming week at the BIO International Convention (BIO 2018).